Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET
Company Participants
Andrea Flynn - Vice President & Head-Investor Relations
Bruce Cozadd - Chairman & Chief Executive Officer
Dan Swisher - President
Rob Iannone - Executive Vice President, Global Head of R&D
Renée Galá - Executive Vice President & Chief Financial Officer
Kim Sablich - Executive Vice President & General Manager, North America
Conference Call Participants
Jessica Fye - JPMorgan
Marc Goodman - SVB Leerink
Ken Cacciatore - Cowen
Jason Gerberry - Bank of America
Brandon Folkes - Cantor
David Amsellem - Piper Sandler
Jeff Hung - Morgan Stanley
Gary Nachman - BMO
Madhu Kumar - Goldman Sachs
Ami Fadia - Needham
Gregory Renza - RBC
Ashwani Verma - UBS
Operator
Ladies and gentlemen, and thank you for standing by. Welcome to the Second Quarter 2022 Jazz Pharmaceuticals Earnings Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions]
I would now like to turn the call over to your host Andrea Flynn, Vice President and Head-Investor Relations. You may begin.
Andrea Flynn
Thank you and good afternoon, everyone. Today, Jazz Pharmaceuticals reported its second quarter 2022 financial results. The slide presentation accompanying this webcast is available on the Investors section of our website. Investors may also refer to the press release we issued earlier today, which is also posted to our website.
On the call today are Bruce Cozadd, Chairman, and Chief Executive Officer; Renée Galá, Executive Vice President and Chief Financial Officer; Dan Swisher, President; and Rob Iannone, Executive Vice President, Global Head of R&D. Kim Sablich, Executive Vice President and General Manager, North America will join the team for Q&A.
On slide 2, I’ll remind you that today’s webcast includes forward-looking statements such as those related to our future financial and operating results, including expectations related to Vision 2025 and our guidance for 2022, growth potential and anticipated development and commercialization milestones and goals, which involve risks and uncertainties that could cause actual events, performance, and results to differ materially from those contained in these forward-looking statements.
We encourage you to review the statements contained in today’s press release, in our slide deck, and in our latest SEC disclosure document, which identify certain factors that may cause the company’s actual events, performance, and results to differ materially from those contained in the forward-looking statements made on today’s webcast. We undertake no duty or obligation to update our forward-looking statements.